Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

Findings, demonstrated by the phase 2 PERLA trial, were presented at the 2024 Society for Immunotherapy of Cancer (SITC ...

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for ...

I have been a cancer doctor for 40 years and have seen our treatments evolve to embrace precision medicine and immunotherapy ... dealing with potentially deadly side effects. One prominent example ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

The combination was generally well tolerated. 46.7% of patients experienced grade 3 or higher treatment-related adverse effects. Most common AE is myelosuppression, GI side effect, and transient ...

Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 monthsBiomarker analysis confirms immune activatio ...

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...